前辉瑞研发主管米凯尔·多尔斯滕加入Formation Bio，担任药物筛选委员会主席，并联合担任其投资顾问委员会主席-动脉网

Former Pfizer R&D Chief Mikael Dolsten Joins Formation Bio to Chair Drug Picking Committee and Co-Chair its Investment Advisory Committee

CISION 等信源发布 2025-04-03 04:00



可切换为仅中文







NEW YORK

纽约

，

April 2, 2025

2025年4月2日

/PRNewswire/ -- Formation Bio, an AI-driven pharmaceutical company revolutionizing drug development, today announced that Mikael Dolsten, MD, PhD, former Chief Scientific Officer and President, Pfizer Research & Development, has joined the company as a strategic advisor. In his role, Dolsten will serve as Chair of the Drug Picking Committee, Co-Chair of the Investment Advisory Committee, and Chair of the Science, Technology, and Product Planning Committee..

/PRNewswire/ -- 由人工智能驱动的制药公司Formation Bio今日宣布，前辉瑞研发部门首席科学官兼总裁Mikael Dolsten博士已加入公司担任战略顾问。Dolsten将担任药物筛选委员会主席、投资咨询委员会联合主席以及科技与产品规划委员会主席。

Dolsten brings decades of experience in drug development and investment, having played a key role in Pfizer's industry-leading R&D efforts, including the rapid development of the COVID-19 vaccine, the oral anti-viral drug Paxlovid, and many blockbuster therapies across a range of therapeutic areas. He concluded his tenure at Pfizer on .

多尔斯滕在药物开发和投资方面拥有数十年的经验，他在辉瑞公司行业领先的研发工作中发挥了关键作用，包括快速开发新冠疫苗、口服抗病毒药物帕克斯洛维德以及众多跨治疗领域的重磅疗法。他于结束了在辉瑞的任期。

March 1, 2025

2025年3月1日

, after more than 15 years of leading the company's R&D strategy, during which he oversaw the development and approval of more than 35 medicines and vaccines and moved over 100 drug candidates through clinical development, shaping global drug innovation at an unprecedented scale.

，在领导公司研发战略的十五年多的时间里，他监督了35种以上药品和疫苗的研发与获批，并推动了100多种候选药物通过临床开发，以前所未有的规模塑造了全球药物创新。

At Formation Bio, he will focus on leading asset selection and drug development strategy, leveraging his extensive global network to identify high-potential assets. More broadly, he will also provide strategic guidance on the company's AI initiatives, advising on the development of its AI platform for asset search, evaluation, and deep research on drug targets to enhance decision-making and accelerate pipeline growth..

在 Formation Bio，他将专注于领导资产选择和药物开发战略，利用其广泛的全球网络识别高潜力资产。更广泛地说，他还将为公司的 AI 计划提供战略指导，就其用于资产搜索、评估和药物靶点深度研究的 AI 平台开发提供建议，以加强决策并加速研发管线的增长。

'The pharmaceutical industry is at an inflection point, where AI is shifting from an experimental tool to a core driver of efficiency and innovation in drug development,' said Mikael Dolsten. 'I have seen firsthand how AI has transformed drug discovery, yet development remains a critical bottleneck.

“制药行业正处于一个转折点，人工智能正从一种实验性工具转变为药物开发效率和创新的核心驱动力，”米卡埃尔·多尔斯特说。“我亲眼目睹了人工智能如何改变了药物发现，但开发仍然是一个关键瓶颈。

Formation Bio is leading the charge in applying AI to streamline and accelerate this process, creating a new paradigm for pharma. Their ability to integrate AI at every stage—from asset selection to clinical execution—positions them to fundamentally reshape the industry. I am excited to work alongside this exceptional team to help bring more innovative therapies to patients faster and more efficiently than ever before.'.

Formation Bio正引领将人工智能应用于简化和加速这一进程，为制药行业创造了一种新的范式。他们能够在从资产选择到临床执行的每个阶段整合人工智能，这使其能够从根本上重塑行业。我非常期待与这支卓越的团队合作，帮助以前所未有的速度和效率为患者带来更多创新疗法。

Formation Bio seamlessly integrates AI across many facets of the drug development lifecycle—from asset sourcing and evaluation to clinical trial execution—aiming to enhance efficiency, reduce costs, and improve success rates. Currently, Formation Bio's pipeline includes four majority-owned assets, with a goal to expand to 10-15 assets over the next 3-5 years..

Formation Bio 在药物开发生命周期的多个方面无缝集成人工智能——从资产来源和评估到临床试验执行——旨在提高效率、降低成本并提高成功率。目前，Formation Bio 的产品线包括四个控股多数的资产，并计划在未来 3 到 5 年内扩展到 10 到 15 个资产。

'Mikael is one of the most respected minds in pharmaceutical R&D, with a track record of shaping some of the most important drug advancements of our time,' said

“米卡埃尔是制药研发领域最受尊敬的智囊之一，有着推动我们这个时代一些最重要药物进展的记录，”

Ben Liu

刘本

, Co-Founder & CEO of Formation Bio. 'His scientific leadership, strategic vision, and ability to bridge cutting-edge research with real-world applications have made a lasting impact on the industry. His involvement with Formation Bio reflects his belief in the transformative power of AI in drug development, and we are incredibly fortunate to have his expertise on board.'.

Formation Bio的联合创始人兼首席执行官。‘他的科学领导力、战略眼光以及将前沿研究与实际应用相结合的能力，对行业产生了深远的影响。他对Formation Bio的参与反映了他对人工智能在药物开发中的变革力量的信心，我们非常幸运能够拥有他的专业知识。’

About Formation Bio:

关于Formation Bio：

Formation Bio is an AI-native pharma company differentiated by radically more efficient drug development. Formation Bio has built technology and AI platforms, processes, and capabilities to accelerate all aspects of drug development and clinical trials. Formation Bio partners, acquires, or in-licenses drugs from pharma companies and biotechs to develop programs past clinical proof of concept and beyond, leveraging their proprietary tech and AI capabilities, ultimately helping to bring new medicines to patients.

Formation Bio是一家由人工智能驱动的制药公司，其显著特点在于药物开发效率大幅提升。Formation Bio构建了技术与人工智能平台、流程及能力，以加速药物开发和临床试验的各个方面。该公司通过合作、收购或许可方式从制药公司和生物技术公司获取药物，利用其专有的技术和人工智能能力，推动项目超越临床概念验证阶段并继续发展，最终助力新药惠及患者。

For more information, please visit .

欲了解更多信息，请访问。

www.formation.bio

。

This press release contains forward-looking statements about Formation Bio's business prospects, pipeline development, and asset expansion plans. These statements are based on current expectations and beliefs but are subject to risks and uncertainties that could cause actual results to differ materially from those projected.

本新闻稿包含有关 Formation Bio 的业务前景、管线开发和资产扩展计划的前瞻性声明。这些声明基于当前的预期和信念，但存在可能导致实际结果与预测结果产生重大差异的风险和不确定性。

Formation Bio undertakes no obligation to update these forward-looking statements as a result of new information or future events..

Formation Bio 不承担因新信息或未来事件而更新这些前瞻性陈述的义务。

Media Contact:

媒体联系人：

Lily Mintz

莉莉·明茨

lily@formation.bio

莉莉@formation.bio

SOURCE Formation Bio

来源形成生物

WANT YOUR COMPANY'S NEWS